The insulin receptor (IR) is a single-pass transmembrane enzymatic receptor that mediates the diverse physiological effects of insulin. It functions as a dimeric protein, with each monomer composed of two peptide chains linked by a disulfide bond: The extracellular α-subunit, which contains the ligand-binding domain, and the transmembrane β-subunit, whose intracellular sequence possesses intrinsic tyrosine kinase activity1. Through alternative splicing of exon 11, transcription of the IR gene gives rise to two IR mRNA variants. IR-A lacks exon 11, while IR-B retains it. Consequently, IR-A and IR-B differ by a 12-amino acid sequence near the C-terminus of the α-subunit, resulting in distinct binding of growth factors besides mature insulin, and varying downstream signaling properties. While both variants exhibit similar affinity for insulin, IR-A has a higher affinity for insulin-like growth factor-II (IGF-II) and proinsulin compared to IR-B. The expression patterns of IR-A and IR-B vary depending on tissue and cell type, and disease state2.
Their differential expression in tissues and disease underscores their unique contribution to physiology and pathology. The choroid plexus (CP), a specialized structure that produces cerebrospinal fluid (CSF) and forms part of the blood-CSF barrier, plays a critical role in nutrient transport, waste clearance, and neuroprotection, especially during inflammation. Both IR isoforms are expressed in the CP, where they likely regulate CSF volume and composition. IR-A, through its high-affinity binding by IGF-II, likely promotes cellular proliferation and tissue repair in the CP epithelium. IR-B, on the other hand, is implicated in insulin transport across the blood-CSF barrier, supporting insulin availability in the brain for astrocytes, neurons, glia, and glucose homeostasis3,4.
Pre-diabetic IR levels have been associated with elevated CSF tau in asymptomatic individuals at genetic risk for Alzheimer's disease (AD)5, and alterations in the IR-A/IR-B ratio have been linked to insulin resistance, aging, and increased proliferative activity-factors that may contribute to cancer and other pathologies6. Identifying isoform-specific expression patterns of IR-A and IR-B represents a critical step toward developing novel therapeutic strategies for complex central nervous system disorders. However, current approaches, such as immunostaining and qPCR, are limited: Not all proteins can be reliably immunolabeled due to a lack of validated antibodies, and while qPCR is highly specific, it lacks spatial resolution.
To overcome these limitations, we utilized Duplex in situ hybridization (ISH), an advanced RNA detection technology based on the RNAscope platform BaseScope. This assay employs a unique double-Z probe design that requires tandem binding to the target RNA, enabling high specificity and sensitivity, even for low-abundance transcripts. The fluorescent or chromogenic signal is amplified through multiple probe-binding events, enhancing detection and reducing background7. Unlike standard RNAscope, this assay is optimized to detect short RNA sequences (50-300 bases), making it particularly suitable for identifying alternative splicing events, single-nucleotide variants, and rare transcripts in complex tissues like the brain8.
This assay visualizes targets simultaneously as distinct green (C1) and red (C2) chromogenic signals under brightfield. It ensures success using tissues fixed in 4% paraformaldehyde (PFA) or 10% neutral buffered formalin (NBF) and sectioned at 5 µm-15 µm (frozen/FFPE), containing low-to-high abundance RNA. Due to sensitivity to RNA degradation, over-fixation, and probe errors, we need to optimize pretreatment, probe design, and controls to maximize specificity and minimize background. Here, we applied this Duplex ISH assay to characterize the expression patterns of IR-A and IR-B in the murine CP, offering new insights into the spatial biology of IR isoforms and their possible roles in brain health and disease.